Discover how deucravacitinib, a first‑in‑class oral TYK2 inhibitor, delivers biologic‑like efficacy in plaque psoriasis with once‑daily dosing, high selectivity, and a potentially improved safety profile compared with traditional JAK inhibitors.
Learn what deucravacitinib is, how its selective TYK2 inhibition differs from traditional JAK inhibitors, and why it’s becoming a leading oral treatment option for moderate-to-severe plaque psoriasis based on Phase 3 POETYK PSO clinical trial data.
Learn what deucravacitinib is, how this first-in-class selective TYK2 inhibitor works, and why it’s changing the treatment landscape for moderate-to-severe plaque psoriasis and other autoimmune diseases, with data from pivotal phase 3 clinical trials.